Congestive Heart Failure Changing population trends
Congestive Heart Failure
Changing population trends
Clinical Scenario
download PPT version here
http://www.ziddu.com/download/7799915/CHF.ppt.html
JB is 75 and is a retired publican. First presented 12 yr ago with MI.
A strong family Hx of CVS disease. Father died at age 40 with Stroke. Mother had angina.
Subsequent LVF 5 yr ago with hospitalization. Echo dilated / asymmetrical contraction / dysynergy.
Ejection Fraction 35%. Effort Dyspnoea
What are the therapeutic options?
Congestive Heart Failure
Incidence and age
Congestive Heart Failure
Changing population trends
Combined all-cause mortality and morbidity (time to event)
Hospitalization for heart failure
Sudden death with resuscitation
Need for intravenous inotropes/vasodilators for worsening HF
All-cause mortality (time to event)
Hospitalization for heart failure
Signs and symptoms of heart failure
NYHA functional class (change from baseline)
Echocardiographic indices of left ventricular function (LVEF and LVIDd — change from baseline)
Quality of life score (Minnesota Living With Heart Failure score)
Mortality and Morbidity Analyses
Primary Endpoint Analyses
Primary Endpoint Sensitivity* Analyses
Effect of Valsartan on Morbidity Endpoint*
All-Cause Mortality:
Kaplan-Meier Analysis (Val-HeFT)*
Mortality by ACE Inhibitor/Beta Blocker Subgroups
HF-Related Hospitalizations*
Changing population trends
Clinical Scenario
download PPT version here
http://www.ziddu.com/download/7799915/CHF.ppt.html
JB is 75 and is a retired publican. First presented 12 yr ago with MI.
A strong family Hx of CVS disease. Father died at age 40 with Stroke. Mother had angina.
Subsequent LVF 5 yr ago with hospitalization. Echo dilated / asymmetrical contraction / dysynergy.
Ejection Fraction 35%. Effort Dyspnoea
What are the therapeutic options?
Congestive Heart Failure
Incidence and age
Congestive Heart Failure
Changing population trends
Mortality and Morbidity Analyses
Primary Endpoint Analyses
Primary Endpoint Sensitivity* Analyses
Effect of Valsartan on Morbidity Endpoint*
All-Cause Mortality:
Kaplan-Meier Analysis (Val-HeFT)*
Mortality by ACE Inhibitor/Beta Blocker Subgroups
HF-Related Hospitalizations*